Price Alert

BioMarin Pharmaceutical I... (BMRN)

NASDAQ: BMRN · Real-Time Price · USD

57.43

0.68 (1.20%)

At close: Sep 05, 2025, 10:05 AM

BioMarin Pharmaceutical Statistics

Share Statistics

BioMarin Pharmaceutical has 192.01M shares outstanding. The number of shares has increased by 0.73% in one year.

Shares Outstanding	192.01M
Shares Change (YoY)	0.73%
Shares Change (QoQ)	0.52%
Owned by Institutions (%)	95.68%
Shares Floating	189.13M
Failed to Deliver (FTD) Shares	1,510
FTD / Avg. Volume	0.07%

Short Selling Information

The latest short interest is 4.96M, so 2.6% of the outstanding shares have been sold short.

Short Interest	4.96M
Short % of Shares Out	2.6%
Short % of Float	2.62%
Short Ratio (days to cover)	1.54

Valuation Ratios

The PE ratio is 29.26 and the forward PE ratio is 12.88. BioMarin Pharmaceutical's PEG ratio is 0.19.

PE Ratio	29.26
Forward PE	12.88
PS Ratio	4.38
Forward PS	3.2
PB Ratio	2.21
P/FCF Ratio	26.27
PEG Ratio	0.19

Financial Ratio History

Enterprise Valuation

BioMarin Pharmaceutical has an Enterprise Value (EV) of 12.15B.

EV / Sales	4.26
EV / EBITDA	18.67
EV / EBIT	21.21
EV / FCF	25.56

Financial Position

The company has a current ratio of 5.33, with a Debt / Equity ratio of 0.11.

Current Ratio	5.33
Quick Ratio	3.29
Debt / Equity	0.11
Debt / EBITDA	0.93
Debt / FCF	1.27
Interest Coverage	38.23

Financial Efficiency

Return on Equity is 7.54% and Return on Invested Capital is 5.97%.

Return on Equity	7.54%
Return on Assets	6.11%
Return on Invested Capital	5.97%
Revenue Per Employee	$938.79K
Profits Per Employee	$140.41K
Employee Count	3,040
Asset Turnover	0.41
Inventory Turnover	0.47

Taxes

Income Tax	114.9M
Effective Tax Rate	21.21%

Stock Price Statistics

The stock price has increased by -33.33% in the last 52 weeks. The beta is 0.35, so BioMarin Pharmaceutical's price volatility has been higher than the market average.

Beta	0.35
52-Week Price Change	-33.33%
50-Day Moving Average	57.95
200-Day Moving Average	62.28
Relative Strength Index (RSI)	43.34
Average Volume (20 Days)	2,140,475

Income Statement

In the last 12 months, BioMarin Pharmaceutical had revenue of 2.85B and earned 426.86M in profits. Earnings per share was 2.25.

Revenue	2.85B
Gross Profit	2.27B
Operating Income	484.21M
Net Income	426.86M
EBITDA	650.86M
EBIT	554.1M
Earnings Per Share (EPS)	2.25

Full Income Statement

Balance Sheet

The company has 942.84M in cash and 602.71M in debt, giving a net cash position of 340.13M.

Cash & Cash Equivalents	942.84M
Total Debt	602.71M
Net Cash	340.13M
Retained Earnings	-194.69M
Total Assets	7.46B
Working Capital	3.12B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 572.84M and capital expenditures -97.42M, giving a free cash flow of 475.42M.

Operating Cash Flow	572.84M
Capital Expenditures	-97.42M
Free Cash Flow	475.42M
FCF Per Share	2.5

Full Cash Flow Statement

Margins

Gross margin is 79.67%, with operating and profit margins of 16.97% and 14.96%.

Gross Margin	79.67%
Operating Margin	16.97%
Pretax Margin	18.98%
Profit Margin	14.96%
EBITDA Margin	22.81%
EBIT Margin	16.97%
FCF Margin	16.66%

Dividends & Yields

BMRN does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	3.42%
FCF Yield	3.81%

Dividend Details

Analyst Forecast

The average price target for BMRN is $92.5, which is 63% higher than the current price. The consensus rating is "Buy".

Price Target	$92.5
Price Target Difference	63%
Analyst Consensus	Buy
Analyst Count	23

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	$11.25
Lynch Upside	-80.18%
Graham Number	38.79
Graham Upside	-31.65%

Scores

Altman Z-Score	6.05
Piotroski F-Score	7